Celularity announced today that the independent Data Monitoring Committee (DMC) completed the first assessment of the ongoing Phase I/II CYNK-001-COVID-19 (CYNKCOVID) study with CYNK-001 off-the-shelf, allogeneic, natural killer (NK) cell therapy in adults with COVID-19.
Celularity announced today that the first patient was dosed in a Phase I/II study of human placental hematopoietic stem cell derived NK cells (CYNK-001) for the treatment of adults with COVID-19 as part of a national clinical trial. The patient was treated at UC Irvine in California, the first CA site to open for patient enrollment with support from a COVID-19 Project grant awarded to Celularity by the California Institute for Regenerative Medicine (CIRM). Participating trial sites include Hackensack University Medical Center and Atlantic Health in New Jersey, MultiCare Health System in Washington State, Banner University Medical Center Phoenix in Arizona, the University of Arkansas in Arkansas, and UC Davis in California. The Principal Investigator is Corey Casper, M.D., MPH, of the Infectious Disease Research Institute (IDRI) ClinicalTrials.gov Identifier: NCT04365101.
Celularity, Inc. (”Celularity” or “the Company”) today announced that it has sold its UltraMIST® Ultrasound Healing Therapy asset to Sanuwave Health, Inc. [OTC PNK: SNWV] (“Sanuwave”) in connection with which Celularity granted Sanuwave certain partnership rights to the Company’s wound care biologic product portfolio.
Celularity today announced that it has been awarded a $750,000 COVID-19 Project grant by the California Institute for Regenerative Medicine (CIRM), one of the three clinical awards targeting the coronavirus. This grant will support California Institutions participating in the Phase I/II clinical trial of human placental hematopoietic stem cell derived natural killer (NK) cells (CYNK-001) for the treatment of adults with COVID-19.
As a company leading the innovation in off-the-shelf cellular medicines for Cancer, Infectious Diseases, and Degenerative Diseases, Celularity has the humble honor of presenting its brand new digital branding package asset with the world.
LifebankUSA, powered by Celularity Inc, and the world’s most comprehensive company for cord, placenta and tissue banking, today unveils a brand new website and announces a relocation to new headquarters in Florham Park, NJ,
The expanded strategic collaboration includes the use of Celularity's proprietary CYNK-001 for treatment of SARS-CoV-2 virus, which causes COVID-19 and Acute Respiratory Distress Syndrome
Therapeutics startup Celularity announced Thursday morning that it has received FDA clearance to begin a clinical trial of a proposed stem-cell treatment for COVID-19. The approval of the New Jersey-based company’s IND application enables the company to begin a clinical trial with patients who have the disease.
Celularity, the venture-backed developer of novel cell therapies for cancer treatments, has received an initial clearance from the Food and Drug Administration to begin early-stage clinical trials on a potential treatment for COVID-19.
The FDA cleared an investigational new drug application for CYNK-001 for the treatment of adults with COVID-19 infection, according to the agent’s manufacturer.
Celularity, a New Jersey company developing experimental cancer treatments derived from human placentas, has received the FDA’s blessing to kick off human testing of its lead immunotherapy for cases of COVID-19 disease.
Celularity, Inc. (“Celularity” or the “Company”), a clinical-stage company developing allogeneic cellular therapies from human placentas, today announced the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) Application for CYNK-001 in patients with glioblastoma multiforme (GBM).
Celularity Announces Positive DMC Safety Review and Continuation of its Phase I/II CYNK-001-COVID-19 (CYNKCOVID) Study
Celularity Doses First Patient in Clinical Trial Evaluating CYNK-001 in COVID-19 Patients
Celularity Announces Sales of UltraMIST® Ultrasound Healing Therapy Asset to Sanuwave Health, Inc.
Celularity announces the activation of first California Clinical Trial Site following CIRM Grant Award to Advance Treatments for COVID-19
Celularity Announces Brand New Website
Lifebank Debuts New Branding & Announces Move to New Facility
Celularity Expands Strategic Collaboration with United Therapeutics Corporation to COVID-19 Infection and Acute Respiratory Distress Syndrome
Celularity Announces FDA Clearance of IND Application for CYNK-001 in Coronavirus, First in Cellular Therapy
FDA Green-Lights Clinical Trial For COVID-19 Coronavirus Treatment That ‘Flattens The Curve’ In Patients
Venture-backed Celularity receives FDA approval for early trials of a new cell therapy for COVID-19
Celularity Gets FDA Approval, Moves Toward New Coronavirus Treatment
FDA clears IND application for natural killer cell-based COVID-19 therapy
Celularity to Test Natural Killer Cell Therapy for Cancer Against COVID
Celularity Announces FDA Clearance of Landmark IND for CYNK-001, an Allogeneic, Off-the-Shelf Cryopreserved NK Cell Therapy